Insmed vs Merck
Insmed (INSM) and Merck (MRK) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $31B
- Last close
- $141.33
- 12 months
- −29.2%
- Market value
- $330B
- Last close
- $133.72
- 12 months
- +40.8%
At a glance
- The biggest part of Insmed's revenue is ARIKAYCE (72%); at Merck it is Pharmaceutical (89%).
- Insmed earns 75% of its revenue in the United States, Merck 56%.
- By market value, Merck ($329.7B) is about 11 times Insmed ($31.0B).
- Over the last 12 months Insmed's share price moved −29.2% and Merck's +40.8%; against the S&P 500 that is −34.9 points and +35.1 points.
- In their last fiscal years Insmed kept -210.5% of revenue as net income and Merck 28.1%.
- In the last 90 days insiders reported 0 open-market purchases at Insmed and 0 at Merck; members of Congress disclosed 0 trades in Insmed and 3 in Merck.
- Next results: Insmed Feb 17, 2027, Merck Feb 2, 2027.
How each one makes money: Insmed revenue · Merck revenue
Share prices on one chart
Insmed and Merck, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Insmed INSMNASDAQ · Pharmaceutical Preparations | Merck MRKNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $31B | $330B |
| Revenue, last fiscal year | $606M | $65B |
| Net income, last fiscal year | −$1.28B | $18.3B |
| Net marginNet income as a share of revenue | -210.5% | 28.1% |
| Free cash flow | −$968M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Merck against
Common questions
How is Insmed different from Merck?
Insmed (INSM) is in Pharmaceutical Preparations on NASDAQ, with $606M of revenue in its last fiscal year and a net margin of -210.5%. Merck (MRK) is in Pharmaceuticals on NYSE, with $65B of revenue in its last fiscal year and a net margin of 28.1%. The biggest part of Insmed's revenue is ARIKAYCE (72%); at Merck it is Pharmaceutical (89%). Insmed earns 75% of its revenue in the United States, Merck 56%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Insmed and Merck compare in size?
Merck has the larger market value: Insmed $31B and Merck $330B, at the last close.
Whose share price rose more over the last 12 months, INSM or MRK?
Over the last 12 months Insmed moved −29.2% and Merck +40.8%. Past price moves say nothing about the future.
Which has had more insider buying, Insmed or Merck?
Since 2006, Insmed insiders reported 81 open-market purchases against 30 for Merck. These are counts of what was filed, not a view on either stock.
Do members of Congress trade INSM or MRK?
In the last 12 months, members of Congress disclosed 1 trades in Insmed (INSM) and 9 in Merck (MRK).
When did insiders last buy INSM and MRK?
Insmed: May 22, 2025. Merck: Feb 7, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Insmed pageMerck pageRare insider trades this weekAll comparisons
https://oqro.io/compare/insm-vs-mrk







